CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Other Events
Item 8.01 Other Events.
On April26, 2017, CRISPR Therapeutics AG (CRISPR) and Intellia
Therapeutics, Inc. (Intellia) announced the expected issuance of
a U.S. patent for CRISPR/Cas9 ribonucleoprotein complexes, to
which CRISPR acquired certain rights as a result of a
cross-option and license agreement with Intellia completed in
connection with the global agreement on foundational intellectual
property for CRISPR/Cas9 gene editing that both companies jointly
announced with the co-owners, licensors and another licensee, on
December16, 2016. Under the cross-option and license agreement,
CRISPR has a royalty-free worldwide sublicense to Intellias
rights to certain intellectual property of Vilnius University.
Intellia and CRISPR are nonexclusive sublicensees for a field of
human therapeutic, prophylactic, and palliative uses (including
companion diagnostics), excluding anti-fungal and anti-microbial
applications. The Vilnius patent claims are directed to
CRISPR/Cas9 complexes assembled in vitro and used for
site-specific modification of target DNA sequences. The patent is
expected to issue to Vilnius on May2, 2017 as U.S. Patent
No.9,637,739. A copy of the press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.
Item9.01.Financial Statements and Exhibits.
(d)Exhibits:
The following exhibits shall be deemed to be furnished, and not
filed:
|
Exhibit No. |
Description |
|
| 99.1 | Press Release, dated April26, 2017. |
About CRISPR THERAPEUTICS AG (NASDAQ:CRSP)
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States. CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Recent Trading Information
CRISPR THERAPEUTICS AG (NASDAQ:CRSP) closed its last trading session up +0.33 at 17.00 with 47,834 shares trading hands.